Skip to main content
YUNNAN BAIYAO GROUP CO.,LTD. logo

YUNNAN BAIYAO GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 000538 ISIN · CNE0000008X7 LEI · 300300ZBV8584FJIG798 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,981 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000538

About YUNNAN BAIYAO GROUP CO.,LTD.

https://www.yunnanbaiyao.com.cn

Yunnan Baiyao Group Co., Ltd. specializes in the research, development, and manufacturing of traditional Chinese medicine (TCM) and modern healthcare products. The company is globally recognized for its proprietary Yunnan Baiyao formula, a protected medicinal secret used for hemostasis, pain relief, and wound healing. Its extensive product portfolio includes pharmaceutical preparations, health supplements, and personal care items, most notably its market-leading medicinal toothpaste and specialized bandages. The group focuses on integrating traditional herbal knowledge with contemporary biotechnology to address needs in oral health, skin care, and pain management. Through a vertically integrated supply chain and robust R&D, the company provides a wide range of therapeutic and consumer health solutions, emphasizing the modernization of TCM for global healthcare standards.

Recent filings

Filing Released Lang Actions
第十一届董事会2026年第四次会议决议公告
Regulatory Filings Classification · 78% confidence The document is a routine announcement of resolutions passed at the company’s board of directors meeting (11th Board, 4th meeting), detailing procedural compliance and voting results. It does not contain actual financial statements (IR/10-K) nor announce changes in Yunnan Baiyao’s own board or senior management appointments (MANG). It is a general regulatory announcement of corporate governance proceedings and therefore fits the fallback “Regulatory Filings” category (RNS).
2026-05-21 Chinese
云南白药独立董事2025年度述职报告-何勇
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 from Yunnan Baiyao Group Co., Ltd. It details the independent director's attendance at board meetings, committee meetings, and shareholder meetings, as well as their activities, evaluations, and compliance with relevant laws and governance standards. The content focuses on the director's duties, participation, and oversight rather than financial results or audit opinions. It is a formal report by an independent director summarizing their work and compliance during their term. This type of document fits best under Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 3039 characters, which is consistent with a detailed report but not a full annual report or audit report. There is no indication of financial statements or earnings data, so it is not an Annual Report (10-K), Audit Report (AR), or Earnings Release (ER). It is also not a regulatory filing or announcement of a report publication. Therefore, the classification is MANG with high confidence.
2026-03-31 Chinese
云南白药独立董事2025年度述职报告-张永良
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 from Yunnan Baiyao Group Co., Ltd. It details the independent director's attendance at board meetings, committee meetings, and shareholder meetings, as well as their activities, evaluations, and compliance with relevant laws and governance standards. The content focuses on the director's duties, participation, and governance oversight rather than financial results or audit opinions. It is a formal report by an independent director on their performance and governance role during their term. This type of document is typically classified under Board/Management Information (MANG) as it relates to board members' roles and governance activities rather than financial reporting or shareholder voting results. The document length is 3422 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification. Therefore, the best fit is MANG with high confidence.
2026-03-31 Chinese
云南白药2025年可持续发展报告
Environmental & Social Information Classification · 95% confidence The document is titled '2025 年可持续发展报告' which translates to '2025 Sustainability Report'. It is described as the second sustainability report by the company, following 18 years of CSR/ESG reporting. The content focuses on environmental, social, and governance (ESG) factors, including governance structure, risk management related to sustainability, environmental impact, social responsibility, and related performance metrics. There is no indication that this is a financial report like an annual or interim report, nor is it an announcement or a transcript. The document is a detailed report on the company's ESG and sustainability performance, which fits the definition of Environmental & Social Information (Code: SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement.
2026-03-31 Chinese
关于2026年度预计日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Yunnan Baiyao Group Co., Ltd. regarding the expected daily related party transactions for the year 2026. It includes detailed information about the estimated transaction amounts with related parties, the nature of these transactions, pricing principles, and the board and independent directors' review and approval. The document is a formal disclosure about related party transactions, which is a regulatory announcement to inform shareholders and the market about these transactions and their compliance with laws and fairness principles. It does not contain financial statements or comprehensive financial performance data, nor is it a report like an annual or interim report. It is not a voting result, management change, or earnings release. It is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS). The document length is over 5,000 characters and contains substantive content, so it is not a mere report publication announcement (RPA).
2026-03-31 Chinese
云南白药集团股份有限公司重大信息内部报告制度
Governance Information Classification · 95% confidence The document is a detailed internal policy manual titled '重大信息内部报告制度' (Major Information Internal Reporting System) for Yunnan Baiyao Group Co., Ltd. It outlines procedures, responsibilities, and definitions related to the internal reporting of major information that could impact the company's stock price or operations. The content includes regulatory references to Chinese securities laws and Shenzhen Stock Exchange rules, and covers internal governance and compliance processes for information disclosure. It does not contain financial statements, earnings data, audit opinions, or shareholder meeting materials. It is not an announcement or a brief notice but a comprehensive governance and compliance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-03-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.